Highlights

  • Tissue Repair Ltd (ASX:TRP) was unchanged at A$0.11 on 13 July 2026, for a market capitalisation of roughly A$6.65 million.
  • Its lead candidate, TR987, is a topical gel in a Phase 3 trial (the TRIVIA study) for chronic venous leg ulcers, built on the company's Glucoprime technology.
  • A pivotal interim analysis on 100 randomised patients is targeted for around June–July 2026 to decide whether continuing the Phase 3 program is warranted or futile.
  • The company reported cash of A$8.229 million at 31 December 2025, with quarterly net operating outflow of A$2.122 million — roughly 3.9 quarters of funding on those figures.
  • Alongside the drug program, Tissue Repair is commercialising TR Pro+, a TGA-listed post-procedure gel, giving it an emerging revenue line but also elevated clinical, funding and execution risk.

A steady session for a wound-healing biotech

Tissue Repair Ltd (ASX:TRP) traded without change on 13 July 2026, its shares recorded at A$0.11 for a 0.00% move, leaving the wound-healing biotech with a market capitalisation of about A$6.65 million — among the smaller names in the ASX health care sector. These figures come from a market snapshot dated 13 July 2026; ASX prices are delayed at least 20 minutes and may have moved since. A flat day is not unusual for a thinly traded micro-cap, but the steady quote arrives at a pivotal moment: Tissue Repair is approaching a make-or-break decision point in its lead clinical program while trying to build a commercial product line. The headline question is whether its regenerative-medicine platform can become a durable growth story.

What happened to Tissue Repair shares?

On 13 July 2026, Tissue Repair (ASX:TRP) shares were unchanged at A$0.11, with no company announcement tied to that specific session. For a stock with a market value under A$7 million and modest turnover, price is usually driven by discrete catalysts — a clinical update, financial report or regulatory decision — rather than continuous news flow, so a flat day is best read as an absence of fresh information.

Was there a verified catalyst?

No specific catalyst was identified for the 13 July 2026 session; the unchanged price appears to reflect an ordinary quiet trading day. The company's most significant near-term catalyst is instead a forthcoming event: the interim analysis of its Phase 3 trial, targeted for around June or July 2026.

What does Tissue Repair (ASX:TRP) do?

Tissue Repair is an Australian clinical-stage biotechnology company developing advanced wound-healing products for chronic wounds and for the aftercare of aesthetic and medical procedures, within the field of regenerative medicine. At its core is a proprietary technology called Glucoprime, a beta-glucan-based active ingredient designed to activate immune cells known as macrophages and stimulate the body's own healing responses. From this platform the company has built two arms — a prescription drug candidate for chronic wounds and a commercial aftercare product line. It is largely pre-commercial, though its aesthetic product has begun modest sales. On 13 July 2026 its market capitalisation stood at roughly A$6.65 million.

Key products, technologies and clinical programs

The lead drug candidate is TR987, a topical gel formulation of Glucoprime being developed for chronic wounds, with its Phase 3 program focused on venous leg ulcers — a common, difficult-to-heal chronic wound. The second arm is TR Pro+, a post-procedure gel used to accelerate healing after cosmetic and medical procedures; unlike the drug candidate, it has secured Listed Medicine status with Australia's Therapeutic Goods Administration (TGA), allowing marketing with healing claims, and has begun generating sales. The company is also developing a wider Glucoprime-based pipeline — a rejuvenating serum, a wound-care gel, a silicone scar-management gel and an anti-bruising product — most at early formulation stages. Investors should distinguish these categories: TR987 is an investigational drug still in clinical trials, while TR Pro+ is a lower-risk, already-marketed listed medicine. Conflating a listed aftercare gel with an approved chronic-wound drug would overstate how far the drug program has progressed.

Clinical-development position

TR987 is being evaluated in a Phase 3 program known as the TRIVIA study (Tissue Repair Gel In Venous Leg Ulcers In AU/US), a randomised, double-blind, multicentre trial comparing TR987 gel plus standard of care against standard of care alone in patients with non-healing venous leg ulcers, with complete ulcer closure at 16 weeks the primary objective and a first patient randomised in early 2025. In its December 2025 quarterly report, the company said its revised core focus was to reach 100 randomised patients by around June or July 2026 to trigger an interim analysis, which an independent statistician and the trial's data safety board would use to determine whether continuing is recommended or futile. As of that report, around 40 patients had been randomised and recruitment had slowed. Reaching an interim futility analysis is not the same as demonstrating success, and the company has said a poor result could lead it to terminate the trial; investors should treat the outcome as genuinely uncertain and binary.

Regulatory and commercial pathway

The two arms differ sharply. For the TR987 drug, the US Food and Drug Administration (FDA) has confirmed it will remain classified as a drug rather than a biologic. Such a drug would ultimately require successful Phase 3 data and formal regulatory review before marketing — a submission is not an approval, and no such approval exists today. For the commercial products, the pathway is further advanced: TR Pro+ holds TGA Listed Medicine status in Australia, and the company is pursuing US 510(k) clearance and CE-mark device pathways — routes generally lower-risk than full drug registration but still incomplete. It sells TR Pro+ in Australia through a partnership with Advanced Cosmeceuticals, which took over distribution from mid-September 2025.

Latest financial position

Tissue Repair reported a cash position of A$8.229 million as at 31 December 2025. During that quarter, net operating cash outflows totalled approximately A$2.122 million, driven mainly by research and development spending — implying an estimated 3.9 quarters of funding on the company's own Appendix 4C. Revenue remains modest: TR Pro+ sales for the quarter were about A$96,000. With less than roughly a year of funding indicated and an elevated burn, the company may need to raise capital or lift revenue; any equity raising would carry dilution risk. All figures are in Australian dollars, for the quarter ended 31 December 2025.

Market opportunity

The commercial logic rests on two large markets. Chronic wounds — including venous leg ulcers, diabetic foot ulcers and pressure injuries — represent a substantial, growing global healthcare burden with many patients poorly served by existing treatments, while the global aesthetics and post-procedure skincare market is large and expanding. The caveat is that a large market only becomes relevant if products succeed clinically, clear regulatory hurdles and gain adoption: for TR987 the opportunity is contingent on an unproven Phase 3 outcome, while for the commercial products it is more immediate but depends on distribution and competition.

Recent official announcements

In its December 2025 quarterly Appendix 4C, released on 30 January 2026, the company detailed the slowdown in trial recruitment, its revised focus on the 100-patient interim analysis by around July 2026, the FDA's confirmation of TR987's drug classification, and progress toward US 510(k) and CE-mark device submissions. The company's ASX announcements remain the authoritative record.

Potential positive considerations

Several factors support a constructive view. TR987 has reached Phase 3 — further than most micro-cap candidates progress — and the company has a defined near-term decision point that will provide clarity. The Glucoprime platform underpins both a drug and a commercial product line, and TR Pro+'s TGA Listed Medicine status and early sales give a lower-risk commercial arm. Should the trial disappoint, management has signalled it would pivot toward commercialisation. None of these removes the underlying uncertainties.

Main risks and uncertainties

The most acute risk is clinical and binary: the TR987 Phase 3 interim analysis could recommend terminating the trial, removing the headline drug opportunity, and recruitment has already slowed. Funding risk is significant — the company indicated less than roughly a year of funding, so additional capital may be required, and any equity raising could dilute shareholders. Commercial revenue is small and dependent on a new distributor, and regulatory risk remains for the pending device and drug pathways. As a small, thinly traded stock, TRP can be volatile. No product of the company's is an approved drug, and a listed medicine is not equivalent to drug approval.

What investors may watch next

The single most important marker is the outcome of the TR987 Phase 3 interim analysis, targeted for around June–July 2026, and whether the company continues or terminates the trial. On the commercial side, investors may watch TR Pro+ sales recovery and progress of the US 510(k) and CE-mark device submissions, while quarterly Appendix 4C reports will show the cash balance, burn rate and any raisings. Outcomes remain subject to clinical, regulatory and commercial developments.

A balanced view on Tissue Repair (ASX:TRP)

Tissue Repair (ASX:TRP) sits at a genuine crossroads. Its regenerative-medicine platform supports both an advanced Phase 3 drug candidate and an already-marketed commercial product line, and the flat share price on 13 July 2026 belies how consequential the coming months could be. A successful interim analysis for TR987 could reframe the company as a credible drug developer; a negative one would push it toward its commercial fallback. Set against that potential are real risks: a binary clinical decision point, a finite cash runway and micro-cap volatility. Whether regenerative medicine becomes Tissue Repair's next major growth story depends on data not yet delivered, subject to clinical, regulatory and funding outcomes. This article is general information only and does not constitute financial or medical advice.